Clinical trial NCT00563381: Tiotropium Once Daily 18 Mcg Versus Salmeterol Twice Daily 50 Mcg on Time to First Exacerbation in COPD Patients.
Official title: Effect of Inhalation of Tiotropium Once Daily 18 Mcg Versus Salmeterol Twice Daily 50 Mcg on Time to First Exacerbation in COPD Patients (a Randomised, Double-blind, Double-dummy, Parallel Group, One-year Study).
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Pulmonary Disease, Chronic Obstructive
Lead sponsor: Boehringer Ingelheim
Sponsor class: INDUSTRY
Collaborators: name: Pfizer
First posted: 2007-11-26
Enrollment: 7376
Sex: ALL
Minimum age (years): 40
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a randomised, double-blind, double-dummy, multinational, multicentre, parallel group trial comparing tiotropium (18 mcg) inhalation capsule via HandiHaler and salmeterol (50 mcg) via MDI in patients with COPD. There will be a two-week run-in period followed by a 52-week randomised treatment phase. Patients who withdraw prematurely from trial medication will be encouraged to remain in the trial and participate in follow-up telephone contacts until their predicted normal exit date from the trial (i.e. 52 weeks after taking the first dose of randomised treatment). The phone calls will be made at all scheduled visits.

The primary objective of this study is to compare the effect of tiotropium (18 mcg) inhalation capsule via HandiHaler with that of salmeterol (50 mcg) via MDI on COPD exacerbations.

The primary endpoint is time to first COPD exacerbation during the 52 week randomised treatment period. A COPD exacerbation will be defined as a complex of respiratory events / symptoms (increase or new onset) of more than one of the following: cough, sputum, wheezing, dyspnoea or chest tightness with at least one symptom lasting at least three days requiring treatment with antibiotics and/or systemic steroids and/or hospitalisation.

The onset of an exacerbation is defined as the onset of the first new or increased reported symptom. The end of the exacerbation should be recorded as defined by the investigator.

Only COPD exacerbations with onset during randomised treatment will be included in the analysis.


Eligibility criteria: Inclusion Criteria:

1. All patients must have a diagnosis of chronic obstructive pulmonary disease (COPD) and must meet the following criteria at Visit 1:

   Patients must have relatively stable, moderate to very severe airway obstruction with a post-bronchodilator FEV1 \<=70% of predicted normal and FEV1 \<=70% of FVC post-bronchodilator (i.e. 30 minutes after inhalation of 4 puffs of 100 µg salbutamol or equivalent SABA). Predicted normal values will be calculated according to ECSC.

   For Height measured in inches Males: FEV1 predicted (L) = 4.30 x (height (inches) / 39.37)-0.029 x age (yrs) - 2.49 Females:FEV1 predicted (L) = 3.95 x (height (inches) / 39.37)-0.025 x age (yrs) - 2.60 For Height measured in metres Males: FEV1 predicted (L) = 4.30 x (height (metres)) - 0.029 x age (years) - 2.49 Females: FEV1 predicted (L) = 3.95 x (height (metres)) - 0.025 x age (years) - 2.60
2. All patients must sign an informed consent consistent with ICH-GCP guidelines prior to participation in the trial.
3. Male or female patients 40 years of age or older.
4. Patients with a history of at least one exacerbation within the past year requiring treatment with either antibiotics and/or systemic steroids and/or hospitalisation.
5. Patients must be current or ex-smokers with a smoking history of \>= 10 pack-years. (Patients who have never smoked cigarettes must be excluded.)
6. Patients must be able to perform all study-related procedures including technically acceptable pulmonary function tests (PFTs).
7. Patients must be able to inhale medication in a competent manner from the HandiHaler and a metered dose inhaler (MDI).
8. Patients must be able to maintain records (patient daily diary card) during the study period as required in the protocol.

Exclusion Criteria:

1. Significant diseases other than COPD. A significant disease is defined as a disease or condition which, in the opinion of the investigator, may put the patient at risk because of participation in the study or may influence either the results of the study or the patients' ability to participate in the study.
2. Patients with a diagnosis of asthma.
3. Patients with a life-threatening pulmonary obstruction, or a history of cystic fibrosis.
4. Patients with known active tuberculosis.
5. Patients with a known symptomatic prostatic hyperplasia or bladder neck obstruction. Patients with symptomatically-controlled prostatic hyperplasia on medication may be included and should continue their medication.
6. Patients with known narrow-angle glaucoma.
7. Patients with a history of myocardial infarction within the year prior to Visit 1.
8. Patients with a history of hospital admission for heart failure within the year prior to Visit 1.
9. Patients with cardiac arrhythmia requiring medical or surgical treatment.
10. Patients with severe cardiovascular disorders.
11. Patients with a known hypersensitivity to anticholinergic drugs, beta-adrenergics, lactose or any other component of the medication delivery system.
12. Patients with known moderate or severe renal insufficiency (known creatinine clearance of \<= 50 mL/min).
13. Patients with untreated known hypokalaemia.
14. Patients with untreated known thyrotoxicosis.
15. Patients with brittle/unstable diabetes mellitus.
16. Patients with a history of and/or active significant alcohol or drug abuse. See exclusion criterion 1.
17. Patients who have taken an investigational drug within 30 days or six half-lives (whichever is greater) prior to Screening Visit (Visit 1).
18. Use of systemic corticosteroid medication at unstable doses (i.e less than six weeks on stable dose) or at doses in excess of the equivalent of 10 mg prednisolone per day or 20 mg every other day.
19. Pregnant or nursing women or women of childbearing potential not using a medically approved means of contraception (i.e oral contraceptives, intrauterine devices, diaphragm or subdermal implants e.g Norplant) for at least three months prior to, and for the duration of the trial.
20. Previous participation (receipt of randomised treatment) in this study.
21. Patients who are currently participating in another study.
22. Patients with any respiratory infection or COPD exacerbation in the four weeks prior to the Screening Visit (Visit 1) or during the run-in period should be postponed. In the case of a respiratory infection or COPD exacerbation during the run-in period, the latter may be extended up to four weeks.

Primary outcomes:
measure: First Occurrence of (Moderate or Severe) COPD Exacerbation
timeFrame: 52 weeks
Secondary outcomes:
measure: COPD Exacerbations Per Patient-year Leading to Hospitalisation
timeFrame: 52 weeks
measure: Number of Participants With at Least One COPD Exacerbation
timeFrame: 52 weeks
measure: COPD Exacerbations Per Patient-year
timeFrame: 52 weeks
measure: First Occurrence of COPD Exacerbation Leading to Hospitalization
timeFrame: 52 weeks
measure: Number of Participants With at Least One COPD Exacerbation Leading to Hospitalisation
timeFrame: 52 weeks
measure: Occurrence of Premature Discontinuation of Trial Medication
timeFrame: 52 weeks
measure: Number of Participants With Premature Discontinuation of Trial Medication
timeFrame: 52 weeks
measure: First Occurrence of COPD Exacerbation or Discontinuation of Trial Medication Because of Worsening of Underlying Disease, Whichever Comes First
timeFrame: 52 weeks
measure: First Occurrence of COPD Exacerbations Treated With Systemic Steroids
timeFrame: 52 weeks
measure: First Occurrence of COPD Exacerbations Treated With Antibiotics
timeFrame: 52 weeks
measure: First Occurrence of COPD Exacerbations Treated With Systemic Steroids and Antibiotics
timeFrame: 52 weeks
measure: COPD Exacerbations Treated With Systemic Steroids Per Patient-year
timeFrame: 52 weeks
measure: COPD Exacerbations Treated With Antibiotics Per Patient-year
timeFrame: 52 weeks
measure: COPD Exacerbations Treated With Systemic Steroids and Antibiotics Per Patient-year
timeFrame: 52 weeks
measure: Pre-dose Morning PEFR Measured by Patients at Home During the First Four Months of Randomised Treatment (Weekly Means Will be Calculated), Week 1
timeFrame: 16 weeks
measure: Pre-dose Morning PEFR Measured by Patients at Home During the First Four Months of Randomised Treatment (Weekly Means Will be Calculated), Week 2
timeFrame: 16 weeks
measure: Pre-dose Morning PEFR Measured by Patients at Home During the First Four Months of Randomised Treatment (Weekly Means Will be Calculated), Week 3
timeFrame: 16 weeks
measure: Pre-dose Morning PEFR Measured by Patients at Home During the First Four Months of Randomised Treatment (Weekly Means Will be Calculated), Week 4
timeFrame: 16 weeks
measure: Pre-dose Morning PEFR Measured by Patients at Home During the First Four Months of Randomised Treatment (Weekly Means Will be Calculated), Week 5
timeFrame: 16 weeks
measure: Pre-dose Morning PEFR Measured by Patients at Home During the First Four Months of Randomised Treatment (Weekly Means Will be Calculated), Week 6
timeFrame: 16 weeks
measure: Pre-dose Morning PEFR Measured by Patients at Home During the First Four Months of Randomised Treatment (Weekly Means Will be Calculated), Week 7
timeFrame: 16 weeks
measure: Pre-dose Morning PEFR Measured by Patients at Home During the First Four Months of Randomised Treatment (Weekly Means Will be Calculated), Week 8
timeFrame: 16 weeks
measure: Pre-dose Morning PEFR Measured by Patients at Home During the First Four Months of Randomised Treatment (Weekly Means Will be Calculated), Week 9
timeFrame: 16 weeks
measure: Pre-dose Morning PEFR Measured by Patients at Home During the First Four Months of Randomised Treatment (Weekly Means Will be Calculated), Week 10
timeFrame: 16 weeks
measure: Pre-dose Morning PEFR Measured by Patients at Home During the First Four Months of Randomised Treatment (Weekly Means Will be Calculated), Week 11
timeFrame: 16 weeks
measure: Pre-dose Morning PEFR Measured by Patients at Home During the First Four Months of Randomised Treatment (Weekly Means Will be Calculated), Week 12
timeFrame: 16 weeks
measure: Pre-dose Morning PEFR Measured by Patients at Home During the First Four Months of Randomised Treatment (Weekly Means Will be Calculated), Week 13
timeFrame: 16 weeks
measure: Pre-dose Morning PEFR Measured by Patients at Home During the First Four Months of Randomised Treatment (Weekly Means Will be Calculated), Week 14
timeFrame: 16 weeks
measure: Pre-dose Morning PEFR Measured by Patients at Home During the First Four Months of Randomised Treatment (Weekly Means Will be Calculated), Week 15
timeFrame: 16 weeks
measure: Pre-dose Morning PEFR Measured by Patients at Home During the First Four Months of Randomised Treatment (Weekly Means Will be Calculated), Week 16
timeFrame: 16 weeks
Other outcomes:
Locations:
city: Feldbach
country: Austria
facility: 205.389.1020 Boehringer Ingelheim Investigational Site
city: Feldkirch
country: Austria
facility: 205.389.1010 Boehringer Ingelheim Investigational Site
city: Grimmenstein/Hochegg
country: Austria
facility: 205.389.1011 Boehringer Ingelheim Investigational Site
city: Gänserndorf
country: Austria
facility: 205.389.1003 Boehringer Ingelheim Investigational Site
city: Hallein
country: Austria
facility: 205.389.1005 Boehringer Ingelheim Investigational Site
city: Linz
country: Austria
facility: 205.389.1023 Boehringer Ingelheim Investigational Site
city: Mittersill
country: Austria
facility: 205.389.1001 Boehringer Ingelheim Investigational Site
city: Salzburg
country: Austria
facility: 205.389.1027 Boehringer Ingelheim Investigational Site
city: Schlüßlberg
country: Austria
facility: 205.389.1026 Boehringer Ingelheim Investigational Site
city: Spittal/Drau
country: Austria
facility: 205.389.1016 Boehringer Ingelheim Investigational Site
city: Steyr
country: Austria
facility: 205.389.1022 Boehringer Ingelheim Investigational Site
city: Wien
country: Austria
facility: 205.389.1002 Boehringer Ingelheim Investigational Site
city: Wien
country: Austria
facility: 205.389.1006 Boehringer Ingelheim Investigational Site
city: Wien
country: Austria
facility: 205.389.1014 Boehringer Ingelheim Investigational Site
city: Wien
country: Austria
facility: 205.389.1018 Boehringer Ingelheim Investigational Site
city: Wien
country: Austria
facility: 205.389.1021 Boehringer Ingelheim Investigational Site
city: Wien
country: Austria
facility: 205.389.1029 Boehringer Ingelheim Investigational Site
city: Zwettl
country: Austria
facility: 205.389.1017 Boehringer Ingelheim Investigational Site
city: Buizingen
country: Belgium
facility: 205.389.1120 Boehringer Ingelheim Investigational Site
city: Cerexhe Heuseux
country: Belgium
facility: 205.389.1124 Boehringer Ingelheim Investigational Site
city: Chenée (Liége)
country: Belgium
facility: 205.389.1116 Boehringer Ingelheim Investigational Site
city: Dour
country: Belgium
facility: 205.389.1121 Boehringer Ingelheim Investigational Site
city: Gembloux
country: Belgium
facility: 205.389.1113 Boehringer Ingelheim Investigational Site
city: Gozée
country: Belgium
facility: 205.389.1117 Boehringer Ingelheim Investigational Site
city: Hasselt
country: Belgium
facility: 205.389.1126 Boehringer Ingelheim Investigational Site
city: Natoye
country: Belgium
facility: 205.389.1129 Boehringer Ingelheim Investigational Site
city: Quaregnon
country: Belgium
facility: 205.389.1130 Boehringer Ingelheim Investigational Site
city: Thuillies
country: Belgium
facility: 205.389.1115 Boehringer Ingelheim Investigational Site
city: Wetteren
country: Belgium
facility: 205.389.1107 Boehringer Ingelheim Investigational Site
city: Pazardjik
country: Bulgaria
facility: 205.389.3911 Boehringer Ingelheim Investigational Site
city: Plovdiv
country: Bulgaria
facility: 205.389.3903 Boehringer Ingelheim Investigational Site
city: Plovdiv
country: Bulgaria
facility: 205.389.3915 Boehringer Ingelheim Investigational Site
city: Rousse
country: Bulgaria
facility: 205.389.3918 Boehringer Ingelheim Investigational Site
city: Sliven
country: Bulgaria
facility: 205.389.3914 Boehringer Ingelheim Investigational Site
city: Sofia
country: Bulgaria
facility: 205.389.3902 Boehringer Ingelheim Investigational Site
city: Sofia
country: Bulgaria
facility: 205.389.3906 Boehringer Ingelheim Investigational Site
city: Sofia
country: Bulgaria
facility: 205.389.3907 Boehringer Ingelheim Investigational Site
city: Stara Zagora
country: Bulgaria
facility: 205.389.3908 Boehringer Ingelheim Investigational Site
city: Troyan
country: Bulgaria
facility: 205.389.3916 Boehringer Ingelheim Investigational Site
city: Varna
country: Bulgaria
facility: 205.389.3912 Boehringer Ingelheim Investigational Site
city: Veliko Turnovo
country: Bulgaria
facility: 205.389.3901 Boehringer Ingelheim Investigational Site
city: Benesov
country: Czech Republic
facility: 205.389.1211 Boehringer Ingelheim Investigational Site
city: Beroun
country: Czech Republic
facility: 205.389.1213 Boehringer Ingelheim Investigational Site
city: Beroun
country: Czech Republic
facility: 205.389.1220 Boehringer Ingelheim Investigational Site
city: Brno-Kralovo Pole
country: Czech Republic
facility: 205.389.1204 Boehringer Ingelheim Investigational Site
city: Cheb
country: Czech Republic
facility: 205.389.1212 Boehringer Ingelheim Investigational Site
city: Havlickuv Brod
country: Czech Republic
facility: 205.389.1205 Boehringer Ingelheim Investigational Site
city: Humpolec
country: Czech Republic
facility: 205.389.1230 Boehringer Ingelheim Investigational Site
city: Jaromer
country: Czech Republic
facility: 205.389.1208 Boehringer Ingelheim Investigational Site
city: Kyjov
country: Czech Republic
facility: 205.389.1219 Boehringer Ingelheim Investigational Site
city: Liberec
country: Czech Republic
facility: 205.389.1225 Boehringer Ingelheim Investigational Site
city: Litomerice
country: Czech Republic
facility: 205.389.1218 Boehringer Ingelheim Investigational Site
city: Lovosice
country: Czech Republic
facility: 205.389.1214 Boehringer Ingelheim Investigational Site
city: Neratovice
country: Czech Republic
facility: 205.389.1207 Boehringer Ingelheim Investigational Site
city: Ostrava
country: Czech Republic
facility: 205.389.1222 Boehringer Ingelheim Investigational Site
city: Plzen
country: Czech Republic
facility: 205.389.1209 Boehringer Ingelheim Investigational Site
city: Plzen
country: Czech Republic
facility: 205.389.1216 Boehringer Ingelheim Investigational Site
city: Praha 13
country: Czech Republic
facility: 205.389.1217 Boehringer Ingelheim Investigational Site
city: Praha 17
country: Czech Republic
facility: 205.389.1215 Boehringer Ingelheim Investigational Site
city: Praha 3
country: Czech Republic
facility: 205.389.1232 Boehringer Ingelheim Investigational Site
city: Praha 4
country: Czech Republic
facility: 205.389.1229 Boehringer Ingelheim Investigational Site
city: Praha 5
country: Czech Republic
facility: 205.389.1223 Boehringer Ingelheim Investigational Site
city: Praha 5
country: Czech Republic
facility: 205.389.1227 Boehringer Ingelheim Investigational Site
city: Praha 6 - Brevnov
country: Czech Republic
facility: 205.389.1224 Boehringer Ingelheim Investigational Site
city: Prerov
country: Czech Republic
facility: 205.389.1228 Boehringer Ingelheim Investigational Site
city: Rokycany
country: Czech Republic
facility: 205.389.1231 Boehringer Ingelheim Investigational Site
city: Strakonice
country: Czech Republic
facility: 205.389.1221 Boehringer Ingelheim Investigational Site
city: Tremosna
country: Czech Republic
facility: 205.389.1206 Boehringer Ingelheim Investigational Site
city: Zatec
country: Czech Republic
facility: 205.389.1201 Boehringer Ingelheim Investigational Site
city: Znojmo
country: Czech Republic
facility: 205.389.1210 Boehringer Ingelheim Investigational Site
city: Copenhagen
country: Denmark
facility: 205.389.1304 Boehringer Ingelheim Investigational Site
city: Frederikssund
country: Denmark
facility: 205.389.1309 Boehringer Ingelheim Investigational Site
city: Helsingor
country: Denmark
facility: 205.389.1301 Boehringer Ingelheim Investigational Site
city: Helsingør
country: Denmark
facility: 205.389.1308 Boehringer Ingelheim Investigational Site
city: Holstebro
country: Denmark
facility: 205.389.1311 Boehringer Ingelheim Investigational Site
city: Næstved
country: Denmark
facility: 205.389.1302 Boehringer Ingelheim Investigational Site
city: Roskilde
country: Denmark
facility: 205.389.1303 Boehringer Ingelheim Investigational Site
city: Skive
country: Denmark
facility: 205.389.1310 Boehringer Ingelheim Investigational Site
city: Sonderborg
country: Denmark
facility: 205.389.1312 Boehringer Ingelheim Investigational Site
city: Værløse
country: Denmark
facility: 205.389.1307 Boehringer Ingelheim Investigational Site
city: Helsinki
country: Finland
facility: 205.389.1402 Boehringer Ingelheim Investigational Site
city: Hyvinkää
country: Finland
facility: 205.389.1416 Boehringer Ingelheim Investigational Site
city: Jyväskylä
country: Finland
facility: 205.389.1410 Boehringer Ingelheim Investigational Site
city: Lahti
country: Finland
facility: 205.389.1404 Boehringer Ingelheim Investigational Site
city: Lappeenranta
country: Finland
facility: 205.389.1417 Boehringer Ingelheim Investigational Site
city: Lohja
country: Finland
facility: 205.389.1415 Boehringer Ingelheim Investigational Site
city: Mikkeli
country: Finland
facility: 205.389.1411 Boehringer Ingelheim Investigational Site
city: Pori
country: Finland
facility: 205.389.1409 Boehringer Ingelheim Investigational Site
city: Preitilä Paimio
country: Finland
facility: 205.389.1412 Boehringer Ingelheim Investigational Site
city: Turku
country: Finland
facility: 205.389.1407 Boehringer Ingelheim Investigational Site
city: Bauge
country: France
facility: 205.389.1607 Boehringer Ingelheim Investigational Site
city: Beauvais
country: France
facility: 205.389.1525 Boehringer Ingelheim Investigational Site
city: Bethune
country: France
facility: 205.389.1523 Boehringer Ingelheim Investigational Site
city: Cestas
country: France
facility: 205.389.1571 Boehringer Ingelheim Investigational Site
city: Charry le Rouet
country: France
facility: 205.389.1561 Boehringer Ingelheim Investigational Site
city: Cholet
country: France
facility: 205.389.1507 Boehringer Ingelheim Investigational Site
city: Ecouflant
country: France
facility: 205.389.1606 Boehringer Ingelheim Investigational Site
city: Ermont
country: France
facility: 205.389.1554 Boehringer Ingelheim Investigational Site
city: La Barre de Monts
country: France
facility: 205.389.1597 Boehringer Ingelheim Investigational Site
city: La Jubaudière
country: France
facility: 205.389.1581 Boehringer Ingelheim Investigational Site
city: La Roche Sur Yon
country: France
facility: 205.389.1536 Boehringer Ingelheim Investigational Site
city: La Roche sur Yon
country: France
facility: 205.389.1598 Boehringer Ingelheim Investigational Site
city: Le Kremlin Bicetre
country: France
facility: 205.389.1501 Boehringer Ingelheim Investigational Site
city: Le Mans Cedex
country: France
facility: 205.389.1503 Boehringer Ingelheim Investigational Site
city: Le Pradet
country: France
facility: 205.389.1586 Boehringer Ingelheim Investigational Site
city: Marseille
country: France
facility: 205.389.1528 Boehringer Ingelheim Investigational Site
city: Marseille
country: France
facility: 205.389.1530 Boehringer Ingelheim Investigational Site
city: Marseille
country: France
facility: 205.389.1558 Boehringer Ingelheim Investigational Site
city: Marseille
country: France
facility: 205.389.1564 Boehringer Ingelheim Investigational Site
city: Marseille
country: France
facility: 205.389.1565 Boehringer Ingelheim Investigational Site
city: Montfermeil
country: France
facility: 205.389.1539 Boehringer Ingelheim Investigational Site
city: Nantes
country: France
facility: 205.389.1608 Boehringer Ingelheim Investigational Site
city: Nice
country: France
facility: 205.389.1526 Boehringer Ingelheim Investigational Site
city: Nimes
country: France
facility: 205.389.1504 Boehringer Ingelheim Investigational Site
city: Ollioules
country: France
facility: 205.389.1502 Boehringer Ingelheim Investigational Site
city: Orleans
country: France
facility: 205.389.1541 Boehringer Ingelheim Investigational Site
city: Perpignan
country: France
facility: 205.389.1527 Boehringer Ingelheim Investigational Site
city: PIERRE BENITE cédex
country: France
facility: 205.389.1532 Boehringer Ingelheim Investigational Site
city: Rennes cedex 9
country: France
facility: 205.389.1553 Boehringer Ingelheim Investigational Site
city: Saint Dié des Vosges
country: France
facility: 205.389.1555 Boehringer Ingelheim Investigational Site
city: Saint Germain du Puch
country: France
facility: 205.389.1575 Boehringer Ingelheim Investigational Site
city: Saint Laurent du Var
country: France
facility: 205.389.1547 Boehringer Ingelheim Investigational Site
city: Saint Laurent
country: France
facility: 205.389.1572 Boehringer Ingelheim Investigational Site
city: Saint Orens de Cameville
country: France
facility: 205.389.1567 Boehringer Ingelheim Investigational Site
city: Saint Pierre Montlimard
country: France
facility: 205.389.1577 Boehringer Ingelheim Investigational Site
city: Saint Quentin
country: France
facility: 205.389.1531 Boehringer Ingelheim Investigational Site
city: Seysses
country: France
facility: 205.389.1569 Boehringer Ingelheim Investigational Site
city: St-Etienne
country: France
facility: 205.389.1514 Boehringer Ingelheim Investigational Site
city: Strasbourg
country: France
facility: 205.389.1510 Boehringer Ingelheim Investigational Site
city: Strasbourg
country: France
facility: 205.389.1522 Boehringer Ingelheim Investigational Site
city: Sélestat
country: France
facility: 205.389.1520 Boehringer Ingelheim Investigational Site
city: Toulon
country: France
facility: 205.389.1512 Boehringer Ingelheim Investigational Site
city: Toulon
country: France
facility: 205.389.1515 Boehringer Ingelheim Investigational Site
city: Toulon
country: France
facility: 205.389.1519 Boehringer Ingelheim Investigational Site
city: Toulon
country: France
facility: 205.389.1588 Boehringer Ingelheim Investigational Site
city: Toulon
country: France
facility: 205.389.1589 Boehringer Ingelheim Investigational Site
city: Toulon
country: France
facility: 205.389.1590 Boehringer Ingelheim Investigational Site
city: Toulon
country: France
facility: 205.389.1595 Boehringer Ingelheim Investigational Site
city: Toulouse
country: France
facility: 205.389.1542 Boehringer Ingelheim Investigational Site
city: Villenave D'ornon
country: France
facility: 205.389.1574 Boehringer Ingelheim Investigational Site
city: Aachen
country: Germany
facility: 205.389.1741 Boehringer Ingelheim Investigational Site
city: Aalen
country: Germany
facility: 205.389.1857 Boehringer Ingelheim Investigational Site
city: Auerbach
country: Germany
facility: 205.389.1934 Boehringer Ingelheim Investigational Site
city: Augsburg
country: Germany
facility: 205.389.1868 Boehringer Ingelheim Investigational Site
city: Augsburg
country: Germany
facility: 205.389.1887 Boehringer Ingelheim Investigational Site
city: Bad Lippspringe
country: Germany
facility: 205.389.1707 Boehringer Ingelheim Investigational Site
city: Bad Pymont
country: Germany
facility: 205.389.1722 Boehringer Ingelheim Investigational Site
city: Bad Wörishofen
country: Germany
facility: 205.389.1850 Boehringer Ingelheim Investigational Site
city: Bahrdorf
country: Germany
facility: 205.389.1765 Boehringer Ingelheim Investigational Site
city: Beckum
country: Germany
facility: 205.389.1792 Boehringer Ingelheim Investigational Site
city: Bensheim
country: Germany
facility: 205.389.1801 Boehringer Ingelheim Investigational Site
city: Bensheim
country: Germany
facility: 205.389.1946 Boehringer Ingelheim Investigational Site
city: Bergisch Gladbach
country: Germany
facility: 205.389.1824 Boehringer Ingelheim Investigational Site
city: Bergkamen
country: Germany
facility: 205.389.1709 Boehringer Ingelheim Investigational Site
city: Berkatal-Frankershausen
country: Germany
facility: 205.389.1750 Boehringer Ingelheim Investigational Site
city: Berlin
country: Germany
facility: 205.389.1701 Boehringer Ingelheim Investigational Site
city: Berlin
country: Germany
facility: 205.389.1743 Boehringer Ingelheim Investigational Site
city: Berlin
country: Germany
facility: 205.389.1769 Boehringer Ingelheim Investigational Site
city: Berlin
country: Germany
facility: 205.389.1789 Boehringer Ingelheim Investigational Site
city: Berlin
country: Germany
facility: 205.389.1790 Boehringer Ingelheim Investigational Site
city: Berlin
country: Germany
facility: 205.389.1847 Boehringer Ingelheim Investigational Site
city: Berlin
country: Germany
facility: 205.389.1855 Boehringer Ingelheim Investigational Site
city: Berlin
country: Germany
facility: 205.389.1861 Boehringer Ingelheim Investigational Site
city: Berlin
country: Germany
facility: 205.389.1862 Boehringer Ingelheim Investigational Site
city: Berlin
country: Germany
facility: 205.389.1867 Boehringer Ingelheim Investigational Site
city: Berlin
country: Germany
facility: 205.389.1903 Boehringer Ingelheim Investigational Site
city: Berlin
country: Germany
facility: 205.389.1931 Boehringer Ingelheim Investigational Site
city: Berlin
country: Germany
facility: 205.389.1932 Boehringer Ingelheim Investigational Site
city: Berlin
country: Germany
facility: 205.389.1937 Boehringer Ingelheim Investigational Site
city: Berlin
country: Germany
facility: 205.389.1960 Boehringer Ingelheim Investigational Site
city: Berlin
country: Germany
facility: 205.389.1969 Boehringer Ingelheim Investigational Site
city: Berlin
country: Germany
facility: 205.389.1981 Boehringer Ingelheim Investigational Site
city: Berlin
country: Germany
facility: 205.389.1983 Boehringer Ingelheim Investigational Site
city: Berlin
country: Germany
facility: 205.389.1984 Boehringer Ingelheim Investigational Site
city: Bocholt
country: Germany
facility: 205.389.1747 Boehringer Ingelheim Investigational Site
city: Bochum
country: Germany
facility: 205.389.1808 Boehringer Ingelheim Investigational Site
city: Bochum
country: Germany
facility: 205.389.1811 Boehringer Ingelheim Investigational Site
city: Bonn
country: Germany
facility: 205.389.1828 Boehringer Ingelheim Investigational Site
city: Bonn
country: Germany
facility: 205.389.1870 Boehringer Ingelheim Investigational Site
city: Borna
country: Germany
facility: 205.389.1705 Boehringer Ingelheim Investigational Site
city: Brandenburg/Havel
country: Germany
facility: 205.389.1809 Boehringer Ingelheim Investigational Site
city: Bruchsal
country: Germany
facility: 205.389.1859 Boehringer Ingelheim Investigational Site
city: Camburg
country: Germany
facility: 205.389.1734 Boehringer Ingelheim Investigational Site
city: Celle
country: Germany
facility: 205.389.1923 Boehringer Ingelheim Investigational Site
city: Coswig
country: Germany
facility: 205.389.1901 Boehringer Ingelheim Investigational Site
city: Cottbus
country: Germany
facility: 205.389.1891 Boehringer Ingelheim Investigational Site
city: Deggendorf
country: Germany
facility: 205.389.1858 Boehringer Ingelheim Investigational Site
city: Donaueschingen
country: Germany
facility: 205.389.1784 Boehringer Ingelheim Investigational Site
city: Dortmund
country: Germany
facility: 205.389.1713 Boehringer Ingelheim Investigational Site
city: Dresden
country: Germany
facility: 205.389.1706 Boehringer Ingelheim Investigational Site
city: Düren
country: Germany
facility: 205.389.1967 Boehringer Ingelheim Investigational Site
city: Engelskirchen
country: Germany
facility: 205.389.1814 Boehringer Ingelheim Investigational Site
city: Ense
country: Germany
facility: 205.389.1773 Boehringer Ingelheim Investigational Site
city: Eppelborn-Bubach
country: Germany
facility: 205.389.1727 Boehringer Ingelheim Investigational Site
city: Erfurt
country: Germany
facility: 205.389.1864 Boehringer Ingelheim Investigational Site
city: Erlangen
country: Germany
facility: 205.389.1940 Boehringer Ingelheim Investigational Site
city: Eschwege
country: Germany
facility: 205.389.1900 Boehringer Ingelheim Investigational Site
city: Essen
country: Germany
facility: 205.389.1758 Boehringer Ingelheim Investigational Site
city: Essen
country: Germany
facility: 205.389.1975 Boehringer Ingelheim Investigational Site
city: Essen
country: Germany
facility: 205.389.1982 Boehringer Ingelheim Investigational Site
city: Ettlingen
country: Germany
facility: 205.389.1724 Boehringer Ingelheim Investigational Site
city: Feldkirchen-Westerham
country: Germany
facility: 205.389.1806 Boehringer Ingelheim Investigational Site
city: Forchheim
country: Germany
facility: 205.389.1976 Boehringer Ingelheim Investigational Site
city: Frankenberg
country: Germany
facility: 205.389.1795 Boehringer Ingelheim Investigational Site
city: Frankfurt/Main
country: Germany
facility: 205.389.1905 Boehringer Ingelheim Investigational Site
city: Fuldatal-Ihringshausen
country: Germany
facility: 205.389.1752 Boehringer Ingelheim Investigational Site
city: Föhren
country: Germany
facility: 205.389.1943 Boehringer Ingelheim Investigational Site
city: Fürth
country: Germany
facility: 205.389.1971 Boehringer Ingelheim Investigational Site
city: Gars
country: Germany
facility: 205.389.1766 Boehringer Ingelheim Investigational Site
city: Gelsenkirchen
country: Germany
facility: 205.389.1977 Boehringer Ingelheim Investigational Site
city: Georgensgmünd
country: Germany
facility: 205.389.1744 Boehringer Ingelheim Investigational Site
city: Gießen
country: Germany
facility: 205.389.1875 Boehringer Ingelheim Investigational Site
city: Gifhorn
country: Germany
facility: 205.389.1836 Boehringer Ingelheim Investigational Site
city: Goch
country: Germany
facility: 205.389.1914 Boehringer Ingelheim Investigational Site
city: Greiz
country: Germany
facility: 205.389.1886 Boehringer Ingelheim Investigational Site
city: Grünberg
country: Germany
facility: 205.389.1768 Boehringer Ingelheim Investigational Site
city: Göttingen
country: Germany
facility: 205.389.1751 Boehringer Ingelheim Investigational Site
city: Hagen
country: Germany
facility: 205.389.1831 Boehringer Ingelheim Investigational Site
city: Halle
country: Germany
facility: 205.389.1827 Boehringer Ingelheim Investigational Site
city: Hamburg
country: Germany
facility: 205.389.1917 Boehringer Ingelheim Investigational Site
city: Hamburg
country: Germany
facility: 205.389.1924 Boehringer Ingelheim Investigational Site
city: Hamburg
country: Germany
facility: 205.389.1925 Boehringer Ingelheim Investigational Site
city: Hamburg
country: Germany
facility: 205.389.1980 Boehringer Ingelheim Investigational Site
city: Hammah
country: Germany
facility: 205.389.1716 Boehringer Ingelheim Investigational Site
city: Hammelburg
country: Germany
facility: 205.389.1702 Boehringer Ingelheim Investigational Site
city: Hannover
country: Germany
facility: 205.389.1802 Boehringer Ingelheim Investigational Site
city: Harsewinkel
country: Germany
facility: 205.389.1712 Boehringer Ingelheim Investigational Site
city: Hauzenberg
country: Germany
facility: 205.389.1738 Boehringer Ingelheim Investigational Site
city: Hemmingen
country: Germany
facility: 205.389.1860 Boehringer Ingelheim Investigational Site
city: Höchstädt
country: Germany
facility: 205.389.1949 Boehringer Ingelheim Investigational Site
city: Ingelheim
country: Germany
facility: 205.389.1726 Boehringer Ingelheim Investigational Site
city: Karlsruhe
country: Germany
facility: 205.389.1873 Boehringer Ingelheim Investigational Site
city: Kaufbeuren
country: Germany
facility: 205.389.1838 Boehringer Ingelheim Investigational Site
city: Koblenz
country: Germany
facility: 205.389.1839 Boehringer Ingelheim Investigational Site
city: Krefeld
country: Germany
facility: 205.389.1881 Boehringer Ingelheim Investigational Site
city: Krumpa
country: Germany
facility: 205.389.1786 Boehringer Ingelheim Investigational Site
city: Käbschütztal-Krögis
country: Germany
facility: 205.389.1704 Boehringer Ingelheim Investigational Site
city: Köln
country: Germany
facility: 205.389.1892 Boehringer Ingelheim Investigational Site
city: Köln
country: Germany
facility: 205.389.1974 Boehringer Ingelheim Investigational Site
city: Köthen
country: Germany
facility: 205.389.1813 Boehringer Ingelheim Investigational Site
city: Landsberg
country: Germany
facility: 205.389.1902 Boehringer Ingelheim Investigational Site
city: Leipzig
country: Germany
facility: 205.389.1837 Boehringer Ingelheim Investigational Site
city: Leipzig
country: Germany
facility: 205.389.1841 Boehringer Ingelheim Investigational Site
city: Leipzig
country: Germany
facility: 205.389.1894 Boehringer Ingelheim Investigational Site
city: Leipzig
country: Germany
facility: 205.389.1908 Boehringer Ingelheim Investigational Site
city: Leonberg
country: Germany
facility: 205.389.1874 Boehringer Ingelheim Investigational Site
city: Limburg
country: Germany
facility: 205.389.1955 Boehringer Ingelheim Investigational Site
city: Lorch
country: Germany
facility: 205.389.1904 Boehringer Ingelheim Investigational Site
city: Lübeck
country: Germany
facility: 205.389.1877 Boehringer Ingelheim Investigational Site
city: Lützen
country: Germany
facility: 205.389.1823 Boehringer Ingelheim Investigational Site
city: Magdeburg
country: Germany
facility: 205.389.1879 Boehringer Ingelheim Investigational Site
city: Mannheim
country: Germany
facility: 205.389.1840 Boehringer Ingelheim Investigational Site
city: Mannheim
country: Germany
facility: 205.389.1978 Boehringer Ingelheim Investigational Site
city: Marburg
country: Germany
facility: 205.389.1866 Boehringer Ingelheim Investigational Site
city: Marburg
country: Germany
facility: 205.389.1871 Boehringer Ingelheim Investigational Site
city: Marburg
country: Germany
facility: 205.389.1926 Boehringer Ingelheim Investigational Site
city: Marl
country: Germany
facility: 205.389.1776 Boehringer Ingelheim Investigational Site
city: Merrbusch
country: Germany
facility: 205.389.1779 Boehringer Ingelheim Investigational Site
city: München
country: Germany
facility: 205.389.1799 Boehringer Ingelheim Investigational Site
city: München
country: Germany
facility: 205.389.1815 Boehringer Ingelheim Investigational Site
city: München
country: Germany
facility: 205.389.1817 Boehringer Ingelheim Investigational Site
city: München
country: Germany
facility: 205.389.1843 Boehringer Ingelheim Investigational Site
city: Neubrandenburg
country: Germany
facility: 205.389.1952 Boehringer Ingelheim Investigational Site
city: Neuss
country: Germany
facility: 205.389.1948 Boehringer Ingelheim Investigational Site
city: Neuwied
country: Germany
facility: 205.389.1958 Boehringer Ingelheim Investigational Site
city: Neuötting
country: Germany
facility: 205.389.1805 Boehringer Ingelheim Investigational Site
city: Niesky
country: Germany
facility: 205.389.1830 Boehringer Ingelheim Investigational Site
city: Nussbach
country: Germany
facility: 205.389.1711 Boehringer Ingelheim Investigational Site
city: Oberdorla
country: Germany
facility: 205.389.1781 Boehringer Ingelheim Investigational Site
city: Paderborn
country: Germany
facility: 205.389.1753 Boehringer Ingelheim Investigational Site
city: Paderborn
country: Germany
facility: 205.389.1810 Boehringer Ingelheim Investigational Site
city: Paderborn
country: Germany
facility: 205.389.1854 Boehringer Ingelheim Investigational Site
city: Pirmasens
country: Germany
facility: 205.389.1756 Boehringer Ingelheim Investigational Site
city: Potsdam
country: Germany
facility: 205.389.1794 Boehringer Ingelheim Investigational Site
city: Potsdam
country: Germany
facility: 205.389.1899 Boehringer Ingelheim Investigational Site
city: Radebeul
country: Germany
facility: 205.389.1842 Boehringer Ingelheim Investigational Site
city: Rathenow
country: Germany
facility: 205.389.1897 Boehringer Ingelheim Investigational Site
city: Raubach
country: Germany
facility: 205.389.1950 Boehringer Ingelheim Investigational Site
city: Riesa
country: Germany
facility: 205.389.1783 Boehringer Ingelheim Investigational Site
city: Riesa
country: Germany
facility: 205.389.1826 Boehringer Ingelheim Investigational Site
city: Rostock
country: Germany
facility: 205.389.1742 Boehringer Ingelheim Investigational Site
city: Rüdersdorf
country: Germany
facility: 205.389.1816 Boehringer Ingelheim Investigational Site
city: Rüsselsheim
country: Germany
facility: 205.389.1883 Boehringer Ingelheim Investigational Site
city: Saarlouis
country: Germany
facility: 205.389.1878 Boehringer Ingelheim Investigational Site
city: Schmallenberg-Grafschaft
country: Germany
facility: 205.389.1833 Boehringer Ingelheim Investigational Site
city: Schmölln
country: Germany
facility: 205.389.1973 Boehringer Ingelheim Investigational Site
city: Schwetzingen
country: Germany
facility: 205.389.1979 Boehringer Ingelheim Investigational Site
city: Simmern
country: Germany
facility: 205.389.1856 Boehringer Ingelheim Investigational Site
city: Solingen
country: Germany
facility: 205.389.1918 Boehringer Ingelheim Investigational Site
city: Steinfurt
country: Germany
facility: 205.389.1822 Boehringer Ingelheim Investigational Site
city: Sulzbach
country: Germany
facility: 205.389.1728 Boehringer Ingelheim Investigational Site
city: Templin
country: Germany
facility: 205.389.1717 Boehringer Ingelheim Investigational Site
city: Treuenbrietzen
country: Germany
facility: 205.389.1882 Boehringer Ingelheim Investigational Site
city: Wallerfing
country: Germany
facility: 205.389.1745 Boehringer Ingelheim Investigational Site
city: Wardenburg
country: Germany
facility: 205.389.1800 Boehringer Ingelheim Investigational Site
city: Weißenhorn
country: Germany
facility: 205.389.1885 Boehringer Ingelheim Investigational Site
city: Westerstede
country: Germany
facility: 205.389.1927 Boehringer Ingelheim Investigational Site
city: Weyhe
country: Germany
facility: 205.389.1825 Boehringer Ingelheim Investigational Site
city: Wiesbaden
country: Germany
facility: 205.389.1863 Boehringer Ingelheim Investigational Site
city: Wilhelmshaven
country: Germany
facility: 205.389.1968 Boehringer Ingelheim Investigational Site
city: Wilster
country: Germany
facility: 205.389.1807 Boehringer Ingelheim Investigational Site
city: Wolfsburg
country: Germany
facility: 205.389.1754 Boehringer Ingelheim Investigational Site
city: Wuppertal
country: Germany
facility: 205.389.1919 Boehringer Ingelheim Investigational Site
city: Zerbst
country: Germany
facility: 205.389.1898 Boehringer Ingelheim Investigational Site
city: Budapest
country: Hungary
facility: 205.389.2001 Boehringer Ingelheim Investigational Site
city: Budapest
country: Hungary
facility: 205.389.2005 Boehringer Ingelheim Investigational Site
city: Budapest
country: Hungary
facility: 205.389.2006 Boehringer Ingelheim Investigational Site
city: Budapest
country: Hungary
facility: 205.389.2009 Boehringer Ingelheim Investigational Site
city: Budapest
country: Hungary
facility: 205.389.2016 Boehringer Ingelheim Investigational Site
city: Budapest
country: Hungary
facility: 205.389.2018 Boehringer Ingelheim Investigational Site
city: Budapest
country: Hungary
facility: 205.389.2027 Boehringer Ingelheim Investigational Site
city: Debrecen
country: Hungary
facility: 205.389.2007 Boehringer Ingelheim Investigational Site
city: Deszk
country: Hungary
facility: 205.389.2035 Boehringer Ingelheim Investigational Site
city: Dunaújváros
country: Hungary
facility: 205.389.2015 Boehringer Ingelheim Investigational Site
city: Füzesabony
country: Hungary
facility: 205.389.2011 Boehringer Ingelheim Investigational Site
city: Gyor
country: Hungary
facility: 205.389.2013 Boehringer Ingelheim Investigational Site
city: Gyula
country: Hungary
facility: 205.389.2028 Boehringer Ingelheim Investigational Site
city: Jászberény
country: Hungary
facility: 205.389.2014 Boehringer Ingelheim Investigational Site
city: Kecskemét
country: Hungary
facility: 205.389.2021 Boehringer Ingelheim Investigational Site
city: Komárom
country: Hungary
facility: 205.389.2025 Boehringer Ingelheim Investigational Site
city: Mosdós
country: Hungary
facility: 205.389.2024 Boehringer Ingelheim Investigational Site
city: Mosonmagyaróvár
country: Hungary
facility: 205.389.2026 Boehringer Ingelheim Investigational Site
city: Nyíregyháza
country: Hungary
facility: 205.389.2031 Boehringer Ingelheim Investigational Site
city: Pécs
country: Hungary
facility: 205.389.2002 Boehringer Ingelheim Investigational Site
city: Ráckeve
country: Hungary
facility: 205.389.2017 Boehringer Ingelheim Investigational Site
city: Siófok
country: Hungary
facility: 205.389.2003 Boehringer Ingelheim Investigational Site
city: Szarvas
country: Hungary
facility: 205.389.2010 Boehringer Ingelheim Investigational Site
city: Szentendre
country: Hungary
facility: 205.389.2019 Boehringer Ingelheim Investigational Site
city: Százhalombatta
country: Hungary
facility: 205.389.2022 Boehringer Ingelheim Investigational Site
city: Tatabánya
country: Hungary
facility: 205.389.2030 Boehringer Ingelheim Investigational Site
city: Törökbálint
country: Hungary
facility: 205.389.2029 Boehringer Ingelheim Investigational Site
city: Veszprém
country: Hungary
facility: 205.389.2020 Boehringer Ingelheim Investigational Site
city: Érd
country: Hungary
facility: 205.389.2008 Boehringer Ingelheim Investigational Site
city: Afula
country: Israel
facility: 205.389.2101 Boehringer Ingelheim Investigational Site
city: Ashkelon
country: Israel
facility: 205.389.2110 Boehringer Ingelheim Investigational Site
city: Be'er-Sheva
country: Israel
facility: 205.389.2106 Boehringer Ingelheim Investigational Site
city: Hadera
country: Israel
facility: 205.389.2112 Boehringer Ingelheim Investigational Site
city: Haifa
country: Israel
facility: 205.389.2107 Boehringer Ingelheim Investigational Site
city: Haifa
country: Israel
facility: 205.389.2111 Boehringer Ingelheim Investigational Site
city: Holon
country: Israel
facility: 205.389.2108 Boehringer Ingelheim Investigational Site
city: Jerusalem
country: Israel
facility: 205.389.2104 Boehringer Ingelheim Investigational Site
city: Jerusalem
country: Israel
facility: 205.389.2114 Boehringer Ingelheim Investigational Site
city: Nahariya
country: Israel
facility: 205.389.2116 Boehringer Ingelheim Investigational Site
city: Petah Tiqwa
country: Israel
facility: 205.389.2102 Boehringer Ingelheim Investigational Site
city: Rehovot
country: Israel
facility: 205.389.2105 Boehringer Ingelheim Investigational Site
city: Tel Hashomer
country: Israel
facility: 205.389.2103 Boehringer Ingelheim Investigational Site
city: Zerifin
country: Israel
facility: 205.389.2117 Boehringer Ingelheim Investigational Site
city: Brescia
country: Italy
facility: 205.389.2211 Boehringer Ingelheim Investigational Site
city: Cagliari
country: Italy
facility: 205.389.2206 Boehringer Ingelheim Investigational Site
city: Catania
country: Italy
facility: 205.389.2223 Boehringer Ingelheim Investigational Site
city: Ferrara
country: Italy
facility: 205.389.2209 Boehringer Ingelheim Investigational Site
city: Genova
country: Italy
facility: 205.389.2214 Boehringer Ingelheim Investigational Site
city: Lecco
country: Italy
facility: 205.389.2215 Boehringer Ingelheim Investigational Site
city: Milano
country: Italy
facility: 205.389.2221 Boehringer Ingelheim Investigational Site
city: Milano
country: Italy
facility: 205.389.2226 Boehringer Ingelheim Investigational Site
city: Modena
country: Italy
facility: 205.389.2224 Boehringer Ingelheim Investigational Site
city: Montescano (PV)
country: Italy
facility: 205.389.2203 Boehringer Ingelheim Investigational Site
city: Napoli
country: Italy
facility: 205.389.2230 Boehringer Ingelheim Investigational Site
city: Novara
country: Italy
facility: 205.389.2201 Boehringer Ingelheim Investigational Site
city: Pavia
country: Italy
facility: 205.389.2229 Boehringer Ingelheim Investigational Site
city: Pisa
country: Italy
facility: 205.389.2227 Boehringer Ingelheim Investigational Site
city: Roma
country: Italy
facility: 205.389.2205 Boehringer Ingelheim Investigational Site
city: Roma
country: Italy
facility: 205.389.2228 Boehringer Ingelheim Investigational Site
city: Sassari
country: Italy
facility: 205.389.2210 Boehringer Ingelheim Investigational Site
city: Treviso
country: Italy
facility: 205.389.2232 Boehringer Ingelheim Investigational Site
city: Balvi
country: Latvia
facility: 205.389.2315 Boehringer Ingelheim Investigational Site
city: Daugavpils
country: Latvia
facility: 205.389.2305 Boehringer Ingelheim Investigational Site
city: Jelgava
country: Latvia
facility: 205.389.2313 Boehringer Ingelheim Investigational Site
city: Kraslava
country: Latvia
facility: 205.389.2311 Boehringer Ingelheim Investigational Site
city: Kuldiga
country: Latvia
facility: 205.389.2312 Boehringer Ingelheim Investigational Site
city: Riga
country: Latvia
facility: 205.389.2301 Boehringer Ingelheim Investigational Site
city: Riga
country: Latvia
facility: 205.389.2303 Boehringer Ingelheim Investigational Site
city: Riga
country: Latvia
facility: 205.389.2307 Boehringer Ingelheim Investigational Site
city: Riga
country: Latvia
facility: 205.389.2310 Boehringer Ingelheim Investigational Site
city: Talsi
country: Latvia
facility: 205.389.2306 Boehringer Ingelheim Investigational Site
city: Tukums
country: Latvia
facility: 205.389.2314 Boehringer Ingelheim Investigational Site
city: Valmiera
country: Latvia
facility: 205.389.2304 Boehringer Ingelheim Investigational Site
city: Ventspils
country: Latvia
facility: 205.389.2302 Boehringer Ingelheim Investigational Site
city: Alytus
country: Lithuania
facility: 205.389.2401 Boehringer Ingelheim Investigational Site
city: Kaunas
country: Lithuania
facility: 205.389.2402 Boehringer Ingelheim Investigational Site
city: Kaunas
country: Lithuania
facility: 205.389.2403 Boehringer Ingelheim Investigational Site
city: Kaunas
country: Lithuania
facility: 205.389.2404 Boehringer Ingelheim Investigational Site
city: Kaunas
country: Lithuania
facility: 205.389.2406 Boehringer Ingelheim Investigational Site
city: Kaunas
country: Lithuania
facility: 205.389.2409 Boehringer Ingelheim Investigational Site
city: Klaipeda
country: Lithuania
facility: 205.389.2407 Boehringer Ingelheim Investigational Site
city: Klaipeda
country: Lithuania
facility: 205.389.2411 Boehringer Ingelheim Investigational Site
city: Siauliai
country: Lithuania
facility: 205.389.2408 Boehringer Ingelheim Investigational Site
city: Utena
country: Lithuania
facility: 205.389.2410 Boehringer Ingelheim Investigational Site
city: Vilnius
country: Lithuania
facility: 205.389.2405 Boehringer Ingelheim Investigational Site
city: Vilnius
country: Lithuania
facility: 205.389.2412 Boehringer Ingelheim Investigational Site
city: Vilnius
country: Lithuania
facility: 205.389.2413 Boehringer Ingelheim Investigational Site
city: Vilnius
country: Lithuania
facility: 205.389.2414 Boehringer Ingelheim Investigational Site
city: Rotterdam
country: Netherlands
facility: 205.389.2504 Boehringer Ingelheim Investigational Site
city: te Leiderdrop
country: Netherlands
facility: 205.389.2508 Boehringer Ingelheim Investigational Site
city: Velp
country: Netherlands
facility: 205.389.2510 Boehringer Ingelheim Investigational Site
city: Zoetermeer
country: Netherlands
facility: 205.389.2511 Boehringer Ingelheim Investigational Site
city: Alesund
country: Norway
facility: 205.389.2614 Boehringer Ingelheim Investigational Site
city: Bekkestua
country: Norway
facility: 205.389.2604 Boehringer Ingelheim Investigational Site
city: Elverum
country: Norway
facility: 205.389.2601 Boehringer Ingelheim Investigational Site
city: Follebu
country: Norway
facility: 205.389.2611 Boehringer Ingelheim Investigational Site
city: Hamar
country: Norway
facility: 205.389.2602 Boehringer Ingelheim Investigational Site
city: Harstad
country: Norway
facility: 205.389.2610 Boehringer Ingelheim Investigational Site
city: Harstad
country: Norway
facility: 205.389.2613 Boehringer Ingelheim Investigational Site
city: Hønefoss
country: Norway
facility: 205.389.2609 Boehringer Ingelheim Investigational Site
city: Lørenskog
country: Norway
facility: 205.389.2608 Boehringer Ingelheim Investigational Site
city: Oslo
country: Norway
facility: 205.389.2605 Boehringer Ingelheim Investigational Site
city: Oslo
country: Norway
facility: 205.389.2612 Boehringer Ingelheim Investigational Site
city: Stavanger
country: Norway
facility: 205.389.2616 Boehringer Ingelheim Investigational Site
city: Bialystok
country: Poland
facility: 205.389.2708 Boehringer Ingelheim Investigational Site
city: Bialystok
country: Poland
facility: 205.389.2744 Boehringer Ingelheim Investigational Site
city: Bialystok
country: Poland
facility: 205.389.2762 Boehringer Ingelheim Investigational Site
city: Bialystok
country: Poland
facility: 205.389.2765 Boehringer Ingelheim Investigational Site
city: Bielsko-Biala
country: Poland
facility: 205.389.2778 Boehringer Ingelheim Investigational Site
city: Bienkowka 410
country: Poland
facility: 205.389.2706 Boehringer Ingelheim Investigational Site
city: Brzesko
country: Poland
facility: 205.389.2750 Boehringer Ingelheim Investigational Site
city: Bydgoszcz
country: Poland
facility: 205.389.2758 Boehringer Ingelheim Investigational Site
city: Bystra
country: Poland
facility: 205.389.2773 Boehringer Ingelheim Investigational Site
city: Chodziez
country: Poland
facility: 205.389.2800 Boehringer Ingelheim Investigational Site
city: Czestochowa
country: Poland
facility: 205.389.2712 Boehringer Ingelheim Investigational Site
city: Czestochowa
country: Poland
facility: 205.389.2774 Boehringer Ingelheim Investigational Site
city: Dzialdowo
country: Poland
facility: 205.389.2815 Boehringer Ingelheim Investigational Site
city: Elblag
country: Poland
facility: 205.389.2787 Boehringer Ingelheim Investigational Site
city: Gdansk
country: Poland
facility: 205.389.2715 Boehringer Ingelheim Investigational Site
city: Gdansk
country: Poland
facility: 205.389.2723 Boehringer Ingelheim Investigational Site
city: Gdansk
country: Poland
facility: 205.389.2743 Boehringer Ingelheim Investigational Site
city: Gdansk
country: Poland
facility: 205.389.2764 Boehringer Ingelheim Investigational Site
city: Gdansk
country: Poland
facility: 205.389.2802 Boehringer Ingelheim Investigational Site
city: Gorzow Wlkp
country: Poland
facility: 205.389.2801 Boehringer Ingelheim Investigational Site
city: Ilawa
country: Poland
facility: 205.389.2805 Boehringer Ingelheim Investigational Site
city: Inowroclaw
country: Poland
facility: 205.389.2791 Boehringer Ingelheim Investigational Site
city: Katowice
country: Poland
facility: 205.389.2705 Boehringer Ingelheim Investigational Site
city: Katowice
country: Poland
facility: 205.389.2749 Boehringer Ingelheim Investigational Site
city: Katowice
country: Poland
facility: 205.389.2771 Boehringer Ingelheim Investigational Site
city: Koszalin
country: Poland
facility: 205.389.2759 Boehringer Ingelheim Investigational Site
city: Krakow
country: Poland
facility: 205.389.2711 Boehringer Ingelheim Investigational Site
city: Krakow
country: Poland
facility: 205.389.2722 Boehringer Ingelheim Investigational Site
city: Krakow
country: Poland
facility: 205.389.2747 Boehringer Ingelheim Investigational Site
city: Krakow
country: Poland
facility: 205.389.2753 Boehringer Ingelheim Investigational Site
city: Krakow
country: Poland
facility: 205.389.2798 Boehringer Ingelheim Investigational Site
city: Kraków
country: Poland
facility: 205.389.2748 Boehringer Ingelheim Investigational Site
city: Kutno
country: Poland
facility: 205.389.2757 Boehringer Ingelheim Investigational Site
city: Leszno
country: Poland
facility: 205.389.2727 Boehringer Ingelheim Investigational Site
city: Lodz
country: Poland
facility: 205.389.2701 Boehringer Ingelheim Investigational Site
city: Lodz
country: Poland
facility: 205.389.2709 Boehringer Ingelheim Investigational Site
city: Lodz
country: Poland
facility: 205.389.2716 Boehringer Ingelheim Investigational Site
city: Lodz
country: Poland
facility: 205.389.2724 Boehringer Ingelheim Investigational Site
city: Lodz
country: Poland
facility: 205.389.2732 Boehringer Ingelheim Investigational Site
city: Lodz
country: Poland
facility: 205.389.2746 Boehringer Ingelheim Investigational Site
city: Lodz
country: Poland
facility: 205.389.2751 Boehringer Ingelheim Investigational Site
city: Lomza
country: Poland
facility: 205.389.2804 Boehringer Ingelheim Investigational Site
city: Lublin
country: Poland
facility: 205.389.2741 Boehringer Ingelheim Investigational Site
city: Lublin
country: Poland
facility: 205.389.2776 Boehringer Ingelheim Investigational Site
city: Lublin
country: Poland
facility: 205.389.2817 Boehringer Ingelheim Investigational Site
city: Olawa
country: Poland
facility: 205.389.2760 Boehringer Ingelheim Investigational Site
city: Olsztyn
country: Poland
facility: 205.389.2756 Boehringer Ingelheim Investigational Site
city: Olsztyn
country: Poland
facility: 205.389.2816 Boehringer Ingelheim Investigational Site
city: Ostrow Wielkopolska
country: Poland
facility: 205.389.2702 Boehringer Ingelheim Investigational Site
city: Pabianice
country: Poland
facility: 205.389.2726 Boehringer Ingelheim Investigational Site
city: Plawno
country: Poland
facility: 205.389.2795 Boehringer Ingelheim Investigational Site
city: Plock
country: Poland
facility: 205.389.2730 Boehringer Ingelheim Investigational Site
city: Poznan
country: Poland
facility: 205.389.2703 Boehringer Ingelheim Investigational Site
city: Poznan
country: Poland
facility: 205.389.2719 Boehringer Ingelheim Investigational Site
city: Poznan
country: Poland
facility: 205.389.2737 Boehringer Ingelheim Investigational Site
city: Poznan
country: Poland
facility: 205.389.2766 Boehringer Ingelheim Investigational Site
city: Poznan
country: Poland
facility: 205.389.2769 Boehringer Ingelheim Investigational Site
city: Poznan
country: Poland
facility: 205.389.2813 Boehringer Ingelheim Investigational Site
city: Proszowice
country: Poland
facility: 205.389.2763 Boehringer Ingelheim Investigational Site
city: Pruszkow
country: Poland
facility: 205.389.2767 Boehringer Ingelheim Investigational Site
city: Radom
country: Poland
facility: 205.389.2768 Boehringer Ingelheim Investigational Site
city: Sandomierz
country: Poland
facility: 205.389.2792 Boehringer Ingelheim Investigational Site
city: Sieradz
country: Poland
facility: 205.389.2781 Boehringer Ingelheim Investigational Site
city: Skierniewice
country: Poland
facility: 205.389.2725 Boehringer Ingelheim Investigational Site
city: Szczecin - Zdunowo
country: Poland
facility: 205.389.2777 Boehringer Ingelheim Investigational Site
city: Szczecin - Zdunowo
country: Poland
facility: 205.389.2782 Boehringer Ingelheim Investigational Site
city: Szczecin
country: Poland
facility: 205.389.2718 Boehringer Ingelheim Investigational Site
city: Szczecin
country: Poland
facility: 205.389.2739 Boehringer Ingelheim Investigational Site
city: Szczecin
country: Poland
facility: 205.389.2772 Boehringer Ingelheim Investigational Site
city: Tarnow
country: Poland
facility: 205.389.2738 Boehringer Ingelheim Investigational Site
city: Tarnow
country: Poland
facility: 205.389.2799 Boehringer Ingelheim Investigational Site
city: Tczew
country: Poland
facility: 205.389.2810 Boehringer Ingelheim Investigational Site
city: Torun
country: Poland
facility: 205.389.2775 Boehringer Ingelheim Investigational Site
city: Tranow
country: Poland
facility: 205.389.2754 Boehringer Ingelheim Investigational Site
city: Turek
country: Poland
facility: 205.389.2806 Boehringer Ingelheim Investigational Site
city: Wabrzenzo
country: Poland
facility: 205.389.2803 Boehringer Ingelheim Investigational Site
city: Warsaw
country: Poland
facility: 205.389.2707 Boehringer Ingelheim Investigational Site
city: Warsaw
country: Poland
facility: 205.389.2714 Boehringer Ingelheim Investigational Site
city: Warsaw
country: Poland
facility: 205.389.2728 Boehringer Ingelheim Investigational Site
city: Warszawa
country: Poland
facility: 205.389.2734 Boehringer Ingelheim Investigational Site
city: Warszawa
country: Poland
facility: 205.389.2812 Boehringer Ingelheim Investigational Site
city: Warszawa
country: Poland
facility: 205.389.2818 Boehringer Ingelheim Investigational Site
city: Wodzislaw Slaski
country: Poland
facility: 205.389.2710 Boehringer Ingelheim Investigational Site
city: Wroclaw
country: Poland
facility: 205.389.2721 Boehringer Ingelheim Investigational Site
city: Wroclaw
country: Poland
facility: 205.389.2731 Boehringer Ingelheim Investigational Site
city: Wroclaw
country: Poland
facility: 205.389.2736 Boehringer Ingelheim Investigational Site
city: Wroclaw
country: Poland
facility: 205.389.2752 Boehringer Ingelheim Investigational Site
city: Wroclaw
country: Poland
facility: 205.389.2761 Boehringer Ingelheim Investigational Site
city: Wroclaw
country: Poland
facility: 205.389.2780 Boehringer Ingelheim Investigational Site
city: Wroclaw
country: Poland
facility: 205.389.2793 Boehringer Ingelheim Investigational Site
city: Zabrze
country: Poland
facility: 205.389.2783 Boehringer Ingelheim Investigational Site
city: Zakopane
country: Poland
facility: 205.389.2735 Boehringer Ingelheim Investigational Site
city: Zgierz
country: Poland
facility: 205.389.2770 Boehringer Ingelheim Investigational Site
city: Angra do Heroísmo
country: Portugal
facility: 205.389.2912 Boehringer Ingelheim Investigational Site
city: Barreiro
country: Portugal
facility: 205.389.2911 Boehringer Ingelheim Investigational Site
city: Faro
country: Portugal
facility: 205.389.2904 Boehringer Ingelheim Investigational Site
city: Figueira da Foz
country: Portugal
facility: 205.389.2910 Boehringer Ingelheim Investigational Site
city: Guarda
country: Portugal
facility: 205.389.2907 Boehringer Ingelheim Investigational Site
city: Lisboa
country: Portugal
facility: 205.389.2914 Boehringer Ingelheim Investigational Site
city: Lisboa
country: Portugal
facility: 205.389.2917 Boehringer Ingelheim Investigational Site
city: Santa Maria da Feira
country: Portugal
facility: 205.389.2905 Boehringer Ingelheim Investigational Site
city: Santiago do Cacem
country: Portugal
facility: 205.389.2909 Boehringer Ingelheim Investigational Site
city: Torres Vedras
country: Portugal
facility: 205.389.2903 Boehringer Ingelheim Investigational Site
city: Brasov
country: Romania
facility: 205.389.3009 Boehringer Ingelheim Investigational Site
city: Brasov
country: Romania
facility: 205.389.3018 Boehringer Ingelheim Investigational Site
city: Brasov
country: Romania
facility: 205.389.3023 Boehringer Ingelheim Investigational Site
city: Bucharest
country: Romania
facility: 205.389.3025 Boehringer Ingelheim Investigational Site
city: Bucuresti
country: Romania
facility: 205.389.3001 Boehringer Ingelheim Investigational Site
city: Bucuresti
country: Romania
facility: 205.389.3002 Boehringer Ingelheim Investigational Site
city: Bucuresti
country: Romania
facility: 205.389.3004 Boehringer Ingelheim Investigational Site
city: Bucuresti
country: Romania
facility: 205.389.3006 Boehringer Ingelheim Investigational Site
city: Bucuresti
country: Romania
facility: 205.389.3007 Boehringer Ingelheim Investigational Site
city: Bucuresti
country: Romania
facility: 205.389.3012 Boehringer Ingelheim Investigational Site
city: Bucuresti
country: Romania
facility: 205.389.3013 Boehringer Ingelheim Investigational Site
city: Constanta
country: Romania
facility: 205.389.3016 Boehringer Ingelheim Investigational Site
city: Constanta
country: Romania
facility: 205.389.3019 Boehringer Ingelheim Investigational Site
city: Craiova
country: Romania
facility: 205.389.3015 Boehringer Ingelheim Investigational Site
city: Iasi
country: Romania
facility: 205.389.3008 Boehringer Ingelheim Investigational Site
city: Iasi
country: Romania
facility: 205.389.3014 Boehringer Ingelheim Investigational Site
city: Iasi
country: Romania
facility: 205.389.3022 Boehringer Ingelheim Investigational Site
city: Iasi
country: Romania
facility: 205.389.3024 Boehringer Ingelheim Investigational Site
city: Oradea
country: Romania
facility: 205.389.3005 Boehringer Ingelheim Investigational Site
city: Tg. Mures
country: Romania
facility: 205.389.3017 Boehringer Ingelheim Investigational Site
city: Timisoara
country: Romania
facility: 205.389.3021 Boehringer Ingelheim Investigational Site
city: Arkhangelsk
country: Russian Federation
facility: 205.389.3174 Boehringer Ingelheim Investigational Site
city: Barnaul
country: Russian Federation
facility: 205.389.3113 Boehringer Ingelheim Investigational Site
city: Barnaul
country: Russian Federation
facility: 205.389.3131 Boehringer Ingelheim Investigational Site
city: Chelyabinsk
country: Russian Federation
facility: 205.389.3105 Boehringer Ingelheim Investigational Site
city: Chelyabinsk
country: Russian Federation
facility: 205.389.3182 Boehringer Ingelheim Investigational Site
city: Chelyabinsk
country: Russian Federation
facility: 205.389.3183 Boehringer Ingelheim Investigational Site
city: Chelyabinsk
country: Russian Federation
facility: 205.389.3184 Boehringer Ingelheim Investigational Site
city: Ekaterinburg
country: Russian Federation
facility: 205.389.3116 Boehringer Ingelheim Investigational Site
city: Ekaterinburg
country: Russian Federation
facility: 205.389.3138 Boehringer Ingelheim Investigational Site
city: Ekaterinburg
country: Russian Federation
facility: 205.389.3148 Boehringer Ingelheim Investigational Site
city: Ekaterinburg
country: Russian Federation
facility: 205.389.3166 Boehringer Ingelheim Investigational Site
city: Gatchina (Leningradskaya oblast)
country: Russian Federation
facility: 205.389.3186 Boehringer Ingelheim Investigational Site
city: Kaliningrad
country: Russian Federation
facility: 205.389.3193 Boehringer Ingelheim Investigational Site
city: Kazan
country: Russian Federation
facility: 205.389.3104 Boehringer Ingelheim Investigational Site
city: Kemerovo
country: Russian Federation
facility: 205.389.3111 Boehringer Ingelheim Investigational Site
city: Kirov
country: Russian Federation
facility: 205.389.3120 Boehringer Ingelheim Investigational Site
city: Krasnodar
country: Russian Federation
facility: 205.389.3170 Boehringer Ingelheim Investigational Site
city: Krasnoyarsk
country: Russian Federation
facility: 205.389.3132 Boehringer Ingelheim Investigational Site
city: Moscow
country: Russian Federation
facility: 205.389.3103 Boehringer Ingelheim Investigational Site
city: Moscow
country: Russian Federation
facility: 205.389.3106 Boehringer Ingelheim Investigational Site
city: Moscow
country: Russian Federation
facility: 205.389.3107 Boehringer Ingelheim Investigational Site
city: Moscow
country: Russian Federation
facility: 205.389.3108 Boehringer Ingelheim Investigational Site
city: Moscow
country: Russian Federation
facility: 205.389.3109 Boehringer Ingelheim Investigational Site
city: Moscow
country: Russian Federation
facility: 205.389.3125 Boehringer Ingelheim Investigational Site
city: Moscow
country: Russian Federation
facility: 205.389.3127 Boehringer Ingelheim Investigational Site
city: Moscow
country: Russian Federation
facility: 205.389.3128 Boehringer Ingelheim Investigational Site
city: Moscow
country: Russian Federation
facility: 205.389.3130 Boehringer Ingelheim Investigational Site
city: Moscow
country: Russian Federation
facility: 205.389.3134 Boehringer Ingelheim Investigational Site
city: Moscow
country: Russian Federation
facility: 205.389.3136 Boehringer Ingelheim Investigational Site
city: Moscow
country: Russian Federation
facility: 205.389.3139 Boehringer Ingelheim Investigational Site
city: Moscow
country: Russian Federation
facility: 205.389.3140 Boehringer Ingelheim Investigational Site
city: Moscow
country: Russian Federation
facility: 205.389.3143 Boehringer Ingelheim Investigational Site
city: Moscow
country: Russian Federation
facility: 205.389.3149 Boehringer Ingelheim Investigational Site
city: Moscow
country: Russian Federation
facility: 205.389.3151 Boehringer Ingelheim Investigational Site
city: Moscow
country: Russian Federation
facility: 205.389.3156 Boehringer Ingelheim Investigational Site
city: Moscow
country: Russian Federation
facility: 205.389.3157 Boehringer Ingelheim Investigational Site
city: Moscow
country: Russian Federation
facility: 205.389.3163 Boehringer Ingelheim Investigational Site
city: Moscow
country: Russian Federation
facility: 205.389.3164 Boehringer Ingelheim Investigational Site
city: Moscow
country: Russian Federation
facility: 205.389.3167 Boehringer Ingelheim Investigational Site
city: Moscow
country: Russian Federation
facility: 205.389.3168 Boehringer Ingelheim Investigational Site
city: Moscow
country: Russian Federation
facility: 205.389.3171 Boehringer Ingelheim Investigational Site
city: Moscow
country: Russian Federation
facility: 205.389.3196 Boehringer Ingelheim Investigational Site
city: Murmansk
country: Russian Federation
facility: 205.389.3188 Boehringer Ingelheim Investigational Site
city: Nizhniy Novgorod
country: Russian Federation
facility: 205.389.3953 Boehringer Ingelheim Investigational Site
city: Nizhny Novgorod
country: Russian Federation
facility: 205.389.3169 Boehringer Ingelheim Investigational Site
city: Novosibirsk
country: Russian Federation
facility: 205.389.3112 Boehringer Ingelheim Investigational Site
city: Novosibirsk
country: Russian Federation
facility: 205.389.3114 Boehringer Ingelheim Investigational Site
city: Novosibirsk
country: Russian Federation
facility: 205.389.3129 Boehringer Ingelheim Investigational Site
city: Novosibirsk
country: Russian Federation
facility: 205.389.3141 Boehringer Ingelheim Investigational Site
city: Novosibirsk
country: Russian Federation
facility: 205.389.3153 Boehringer Ingelheim Investigational Site
city: Novosibirsk
country: Russian Federation
facility: 205.389.3175 Boehringer Ingelheim Investigational Site
city: Orenburg
country: Russian Federation
facility: 205.389.3126 Boehringer Ingelheim Investigational Site
city: Perm
country: Russian Federation
facility: 205.389.3185 Boehringer Ingelheim Investigational Site
city: Petrozavodsk
country: Russian Federation
facility: 205.389.3192 Boehringer Ingelheim Investigational Site
city: Pskov
country: Russian Federation
facility: 205.389.3179 Boehringer Ingelheim Investigational Site
city: Pskov
country: Russian Federation
facility: 205.389.3190 Boehringer Ingelheim Investigational Site
city: Pyatigorsk,
country: Russian Federation
facility: 205.389.3199 Boehringer Ingelheim Investigational Site
city: Rostov-on-Don
country: Russian Federation
facility: 205.389.3159 Boehringer Ingelheim Investigational Site
city: Ryazan
country: Russian Federation
facility: 205.389.3197 Boehringer Ingelheim Investigational Site
city: Saint Petersburg
country: Russian Federation
facility: 205.389.3198 Boehringer Ingelheim Investigational Site
city: Saratov
country: Russian Federation
facility: 205.389.3110 Boehringer Ingelheim Investigational Site
city: Saratov
country: Russian Federation
facility: 205.389.3951 Boehringer Ingelheim Investigational Site
city: St-Petersburg
country: Russian Federation
facility: 205.389.3191 Boehringer Ingelheim Investigational Site
city: St. Petersburg
country: Russian Federation
facility: 205.389.3119 Boehringer Ingelheim Investigational Site
city: St. Petersburg
country: Russian Federation
facility: 205.389.3121 Boehringer Ingelheim Investigational Site
city: St. Petersburg
country: Russian Federation
facility: 205.389.3122 Boehringer Ingelheim Investigational Site
city: St. Petersburg
country: Russian Federation
facility: 205.389.3123 Boehringer Ingelheim Investigational Site
city: St. Petersburg
country: Russian Federation
facility: 205.389.3135 Boehringer Ingelheim Investigational Site
city: St. Petersburg
country: Russian Federation
facility: 205.389.3137 Boehringer Ingelheim Investigational Site
city: St. Petersburg
country: Russian Federation
facility: 205.389.3145 Boehringer Ingelheim Investigational Site
city: St. Petersburg
country: Russian Federation
facility: 205.389.3146 Boehringer Ingelheim Investigational Site
city: St. Petersburg
country: Russian Federation
facility: 205.389.3160 Boehringer Ingelheim Investigational Site
city: St. Petersburg
country: Russian Federation
facility: 205.389.3161 Boehringer Ingelheim Investigational Site
city: St. Petersburg
country: Russian Federation
facility: 205.389.3176 Boehringer Ingelheim Investigational Site
city: St. Petersburg
country: Russian Federation
facility: 205.389.3177 Boehringer Ingelheim Investigational Site
city: St. Petersburg
country: Russian Federation
facility: 205.389.3178 Boehringer Ingelheim Investigational Site
city: St. Petersburg
country: Russian Federation
facility: 205.389.3180 Boehringer Ingelheim Investigational Site
city: St. Petersburg
country: Russian Federation
facility: 205.389.3181 Boehringer Ingelheim Investigational Site
city: St. Petersburg
country: Russian Federation
facility: 205.389.3189 Boehringer Ingelheim Investigational Site
city: St. Petersburg
country: Russian Federation
facility: 205.389.3195 Boehringer Ingelheim Investigational Site
city: St. Petersburg
country: Russian Federation
facility: 205.389.3950 Boehringer Ingelheim Investigational Site
city: St.Peterburg
country: Russian Federation
facility: 205.389.3165 Boehringer Ingelheim Investigational Site
city: St.Petersburg
country: Russian Federation
facility: 205.389.3117 Boehringer Ingelheim Investigational Site
city: St.Petersburg
country: Russian Federation
facility: 205.389.3147 Boehringer Ingelheim Investigational Site
city: St.Petersburg
country: Russian Federation
facility: 205.389.3152 Boehringer Ingelheim Investigational Site
city: Tomsk
country: Russian Federation
facility: 205.389.3101 Boehringer Ingelheim Investigational Site
city: Tomsk
country: Russian Federation
facility: 205.389.3102 Boehringer Ingelheim Investigational Site
city: Tomsk
country: Russian Federation
facility: 205.389.3133 Boehringer Ingelheim Investigational Site
city: Tomsk
country: Russian Federation
facility: 205.389.3144 Boehringer Ingelheim Investigational Site
city: Velikiy Novgorod
country: Russian Federation
facility: 205.389.3194 Boehringer Ingelheim Investigational Site
city: Yaroslavl
country: Russian Federation
facility: 205.389.3118 Boehringer Ingelheim Investigational Site
city: Yaroslavl
country: Russian Federation
facility: 205.389.3155 Boehringer Ingelheim Investigational Site
city: Bratislava
country: Slovakia
facility: 205.389.3208 Boehringer Ingelheim Investigational Site
city: Kosice
country: Slovakia
facility: 205.389.3204 Boehringer Ingelheim Investigational Site
city: Kosice
country: Slovakia
facility: 205.389.3209 Boehringer Ingelheim Investigational Site
city: Prievidza
country: Slovakia
facility: 205.389.3205 Boehringer Ingelheim Investigational Site
city: Revuca
country: Slovakia
facility: 205.389.3210 Boehringer Ingelheim Investigational Site
city: Spisska Nova Ves
country: Slovakia
facility: 205.389.3203 Boehringer Ingelheim Investigational Site
city: Trnava
country: Slovakia
facility: 205.389.3202 Boehringer Ingelheim Investigational Site
city: Vrable
country: Slovakia
facility: 205.389.3207 Boehringer Ingelheim Investigational Site
city: Golnik
country: Slovenia
facility: 205.389.3301 Boehringer Ingelheim Investigational Site
city: Grosuplje
country: Slovenia
facility: 205.389.3308 Boehringer Ingelheim Investigational Site
city: Jesenice
country: Slovenia
facility: 205.389.3304 Boehringer Ingelheim Investigational Site
city: Kamnik
country: Slovenia
facility: 205.389.3302 Boehringer Ingelheim Investigational Site
city: Ljubljana
country: Slovenia
facility: 205.389.3303 Boehringer Ingelheim Investigational Site
city: Topolsica
country: Slovenia
facility: 205.389.3306 Boehringer Ingelheim Investigational Site
city: Badajoz
country: Spain
facility: 205.389.3410 Boehringer Ingelheim Investigational Site
city: Badalona (Barcelona)
country: Spain
facility: 205.389.3403 Boehringer Ingelheim Investigational Site
city: Barcelona
country: Spain
facility: 205.389.3401 Boehringer Ingelheim Investigational Site
city: Barcelona
country: Spain
facility: 205.389.3402 Boehringer Ingelheim Investigational Site
city: Barcelona
country: Spain
facility: 205.389.3428 Boehringer Ingelheim Investigational Site
city: Cartagena
country: Spain
facility: 205.389.3430 Boehringer Ingelheim Investigational Site
city: Cáceres
country: Spain
facility: 205.389.3416 Boehringer Ingelheim Investigational Site
city: Elche
country: Spain
facility: 205.389.3425 Boehringer Ingelheim Investigational Site
city: Las Palmas de Gran Canarias
country: Spain
facility: 205.389.3408 Boehringer Ingelheim Investigational Site
city: Lleida
country: Spain
facility: 205.389.3405 Boehringer Ingelheim Investigational Site
city: Madrid
country: Spain
facility: 205.389.3404 Boehringer Ingelheim Investigational Site
city: Madrid
country: Spain
facility: 205.389.3406 Boehringer Ingelheim Investigational Site
city: Málaga
country: Spain
facility: 205.389.3414 Boehringer Ingelheim Investigational Site
city: Pontevedra
country: Spain
facility: 205.389.3431 Boehringer Ingelheim Investigational Site
city: Requena
country: Spain
facility: 205.389.3419 Boehringer Ingelheim Investigational Site
city: Reus
country: Spain
facility: 205.389.3427 Boehringer Ingelheim Investigational Site
city: Sagunto
country: Spain
facility: 205.389.3422 Boehringer Ingelheim Investigational Site
city: San Juan
country: Spain
facility: 205.389.3420 Boehringer Ingelheim Investigational Site
city: Santander
country: Spain
facility: 205.389.3415 Boehringer Ingelheim Investigational Site
city: Santiago de Compostela
country: Spain
facility: 205.389.3421 Boehringer Ingelheim Investigational Site
city: Terrasa (Barcelona)
country: Spain
facility: 205.389.3407 Boehringer Ingelheim Investigational Site
city: Valencia
country: Spain
facility: 205.389.3413 Boehringer Ingelheim Investigational Site
city: Valencia
country: Spain
facility: 205.389.3426 Boehringer Ingelheim Investigational Site
city: Valladolid
country: Spain
facility: 205.389.3417 Boehringer Ingelheim Investigational Site
city: Adana
country: Turkey
facility: 205.389.3821 Boehringer Ingelheim Investigational Site
city: Ankara
country: Turkey
facility: 205.389.3808 Boehringer Ingelheim Investigational Site
city: Ankara
country: Turkey
facility: 205.389.3810 Boehringer Ingelheim Investigational Site
city: Bursa
country: Turkey
facility: 205.389.3817 Boehringer Ingelheim Investigational Site
city: Erzurum
country: Turkey
facility: 205.389.3819 Boehringer Ingelheim Investigational Site
city: Istanbul
country: Turkey
facility: 205.389.3812 Boehringer Ingelheim Investigational Site
city: Izmir
country: Turkey
facility: 205.389.3827 Boehringer Ingelheim Investigational Site
city: Izmit
country: Turkey
facility: 205.389.3813 Boehringer Ingelheim Investigational Site
city: Kahramanmaras
country: Turkey
facility: 205.389.3820 Boehringer Ingelheim Investigational Site
city: Malatya
country: Turkey
facility: 205.389.3825 Boehringer Ingelheim Investigational Site
city: Sihhiye Ankara
country: Turkey
facility: 205.389.3809 Boehringer Ingelheim Investigational Site
city: Yenisehir-IZMIR
country: Turkey
facility: 205.389.3807 Boehringer Ingelheim Investigational Site
city: AR Crimea
country: Ukraine
facility: 205.389.3521 Boehringer Ingelheim Investigational Site
city: Cherkassy
country: Ukraine
facility: 205.389.3516 Boehringer Ingelheim Investigational Site
city: Chernivtsi
country: Ukraine
facility: 205.389.3549 Boehringer Ingelheim Investigational Site
city: Dnipropetrovsk
country: Ukraine
facility: 205.389.3509 Boehringer Ingelheim Investigational Site
city: Dnipropetrovsk
country: Ukraine
facility: 205.389.3510 Boehringer Ingelheim Investigational Site
city: Dnipropetrovsk
country: Ukraine
facility: 205.389.3511 Boehringer Ingelheim Investigational Site
city: Dnipropetrovsk
country: Ukraine
facility: 205.389.3523 Boehringer Ingelheim Investigational Site
city: Donetsk
country: Ukraine
facility: 205.389.3514 Boehringer Ingelheim Investigational Site
city: Donetsk
country: Ukraine
facility: 205.389.3524 Boehringer Ingelheim Investigational Site
city: Ivano-Frankivsk
country: Ukraine
facility: 205.389.3533 Boehringer Ingelheim Investigational Site
city: Kharkiv
country: Ukraine
facility: 205.389.3506 Boehringer Ingelheim Investigational Site
city: Kharkiv
country: Ukraine
facility: 205.389.3507 Boehringer Ingelheim Investigational Site
city: Kharkiv
country: Ukraine
facility: 205.389.3508 Boehringer Ingelheim Investigational Site
city: Kharkiv
country: Ukraine
facility: 205.389.3520 Boehringer Ingelheim Investigational Site
city: Kharkiv
country: Ukraine
facility: 205.389.3522 Boehringer Ingelheim Investigational Site
city: Kharkiv
country: Ukraine
facility: 205.389.3532 Boehringer Ingelheim Investigational Site
city: Kharkiv
country: Ukraine
facility: 205.389.3539 Boehringer Ingelheim Investigational Site
city: Kharkiv
country: Ukraine
facility: 205.389.3541 Boehringer Ingelheim Investigational Site
city: Kharkiv
country: Ukraine
facility: 205.389.3543 Boehringer Ingelheim Investigational Site
city: Kharkiv
country: Ukraine
facility: 205.389.3555 Boehringer Ingelheim Investigational Site
city: Kiev
country: Ukraine
facility: 205.389.3501 Boehringer Ingelheim Investigational Site
city: Kiev
country: Ukraine
facility: 205.389.3502 Boehringer Ingelheim Investigational Site
city: Kiev
country: Ukraine
facility: 205.389.3503 Boehringer Ingelheim Investigational Site
city: Kiev
country: Ukraine
facility: 205.389.3550 Boehringer Ingelheim Investigational Site
city: Kiev
country: Ukraine
facility: 205.389.3552 Boehringer Ingelheim Investigational Site
city: Kiev
country: Ukraine
facility: 205.389.3553 Boehringer Ingelheim Investigational Site
city: Kyiv
country: Ukraine
facility: 205.389.3504 Boehringer Ingelheim Investigational Site
city: Kyiv
country: Ukraine
facility: 205.389.3525 Boehringer Ingelheim Investigational Site
city: Kyiv
country: Ukraine
facility: 205.389.3526 Boehringer Ingelheim Investigational Site
city: Kyiv
country: Ukraine
facility: 205.389.3528 Boehringer Ingelheim Investigational Site
city: Kyiv
country: Ukraine
facility: 205.389.3534 Boehringer Ingelheim Investigational Site
city: Kyiv
country: Ukraine
facility: 205.389.3535 Boehringer Ingelheim Investigational Site
city: Kyiv
country: Ukraine
facility: 205.389.3536 Boehringer Ingelheim Investigational Site
city: Kyiv
country: Ukraine
facility: 205.389.3538 Boehringer Ingelheim Investigational Site
city: Kyiv
country: Ukraine
facility: 205.389.3551 Boehringer Ingelheim Investigational Site
city: Lugansk
country: Ukraine
facility: 205.389.3545 Boehringer Ingelheim Investigational Site
city: Lviv
country: Ukraine
facility: 205.389.3512 Boehringer Ingelheim Investigational Site
city: Lviv
country: Ukraine
facility: 205.389.3530 Boehringer Ingelheim Investigational Site
city: Lviv
country: Ukraine
facility: 205.389.3540 Boehringer Ingelheim Investigational Site
city: Lviv
country: Ukraine
facility: 205.389.3554 Boehringer Ingelheim Investigational Site
city: m.Donetsk
country: Ukraine
facility: 205.389.3556 Boehringer Ingelheim Investigational Site
city: m.Odesa
country: Ukraine
facility: 205.389.3513 Boehringer Ingelheim Investigational Site
city: Odesa
country: Ukraine
facility: 205.389.3519 Boehringer Ingelheim Investigational Site
city: Odesa
country: Ukraine
facility: 205.389.3542 Boehringer Ingelheim Investigational Site
city: Odessa
country: Ukraine
facility: 205.389.3527 Boehringer Ingelheim Investigational Site
city: Poltava
country: Ukraine
facility: 205.389.3531 Boehringer Ingelheim Investigational Site
city: Simferopil
country: Ukraine
facility: 205.389.3517 Boehringer Ingelheim Investigational Site
city: Ternopil
country: Ukraine
facility: 205.389.3518 Boehringer Ingelheim Investigational Site
city: Vinnitsa
country: Ukraine
facility: 205.389.3529 Boehringer Ingelheim Investigational Site
city: Zaporizhzhya
country: Ukraine
facility: 205.389.3515 Boehringer Ingelheim Investigational Site
city: Zaporizhzhya
country: Ukraine
facility: 205.389.3547 Boehringer Ingelheim Investigational Site
city: Zaporizhzhya
country: Ukraine
facility: 205.389.3548 Boehringer Ingelheim Investigational Site
city: Bath
country: United Kingdom
facility: 205.389.3601 Boehringer Ingelheim Investigational Site
city: Bexhill on Sea
country: United Kingdom
facility: 205.389.3630 Boehringer Ingelheim Investigational Site
city: Bexhill-on-Sea
country: United Kingdom
facility: 205.389.3636 Boehringer Ingelheim Investigational Site
city: Birmingham
country: United Kingdom
facility: 205.389.3608 Boehringer Ingelheim Investigational Site
city: Blackburn
country: United Kingdom
facility: 205.389.3605 Boehringer Ingelheim Investigational Site
city: Bolton
country: United Kingdom
facility: 205.389.3609 Boehringer Ingelheim Investigational Site
city: Burbage
country: United Kingdom
facility: 205.389.3640 Boehringer Ingelheim Investigational Site
city: Chesterfield
country: United Kingdom
facility: 205.389.3643 Boehringer Ingelheim Investigational Site
city: Corsham
country: United Kingdom
facility: 205.389.3627 Boehringer Ingelheim Investigational Site
city: Coventry
country: United Kingdom
facility: 205.389.3606 Boehringer Ingelheim Investigational Site
city: Coventry
country: United Kingdom
facility: 205.389.3633 Boehringer Ingelheim Investigational Site
city: Frome
country: United Kingdom
facility: 205.389.3639 Boehringer Ingelheim Investigational Site
city: Glasgow
country: United Kingdom
facility: 205.389.3602 Boehringer Ingelheim Investigational Site
city: Irvine
country: United Kingdom
facility: 205.389.3632 Boehringer Ingelheim Investigational Site
city: London
country: United Kingdom
facility: 205.389.3623 Boehringer Ingelheim Investigational Site
city: Middlesex
country: United Kingdom
facility: 205.389.3638 Boehringer Ingelheim Investigational Site
city: Newcastle upon Tyne
country: United Kingdom
facility: 205.389.3616 Boehringer Ingelheim Investigational Site
city: Paisley
country: United Kingdom
facility: 205.389.3618 Boehringer Ingelheim Investigational Site
city: Radstock
country: United Kingdom
facility: 205.389.3622 Boehringer Ingelheim Investigational Site
city: Randalstown
country: United Kingdom
facility: 205.389.3626 Boehringer Ingelheim Investigational Site
city: Soham
country: United Kingdom
facility: 205.389.3604 Boehringer Ingelheim Investigational Site
city: St Just, Penzance
country: United Kingdom
facility: 205.389.3613 Boehringer Ingelheim Investigational Site
city: Sunderland
country: United Kingdom
facility: 205.389.3624 Boehringer Ingelheim Investigational Site
city: Wansford, Peterborough
country: United Kingdom
facility: 205.389.3635 Boehringer Ingelheim Investigational Site
city: Windsor
country: United Kingdom
facility: 205.389.3631 Boehringer Ingelheim Investigational Site
city: Wrexham
country: United Kingdom
facility: 205.389.3612 Boehringer Ingelheim Investigational Site
Study officials:
affiliation: Boehringer Ingelheim
name: Boehringer Ingelheim
role: STUDY_CHAIR
References:
citation: Vogelmeier CF, Asijee GM, Kupas K, Beeh KM. Tiotropium and Salmeterol in COPD Patients at Risk of Exacerbations: A Post Hoc Analysis from POET-COPD((R)). Adv Ther. 2015 Jun;32(6):537-47. doi: 10.1007/s12325-015-0216-2. Epub 2015 Jun 23.
citation: Rabe KF, Fabbri LM, Israel E, Kogler H, Riemann K, Schmidt H, Glaab T, Vogelmeier CF. Effect of ADRB2 polymorphisms on the efficacy of salmeterol and tiotropium in preventing COPD exacerbations: a prespecified substudy of the POET-COPD trial. Lancet Respir Med. 2014 Jan;2(1):44-53. doi: 10.1016/S2213-2600(13)70248-0. Epub 2013 Dec 5.
citation: Beeh KM, Glaab T, Stowasser S, Schmidt H, Fabbri LM, Rabe KF, Vogelmeier CF. Characterisation of exacerbation risk and exacerbator phenotypes in the POET-COPD trial. Respir Res. 2013 Oct 29;14(1):116. doi: 10.1186/1465-9921-14-116.
citation: Rabe KF, Fabbri LM, Vogelmeier C, Kogler H, Schmidt H, Beeh KM, Glaab T. Seasonal distribution of COPD exacerbations in the Prevention of Exacerbations with Tiotropium in COPD trial. Chest. 2013 Mar;143(3):711-719. doi: 10.1378/chest.12-1277.
citation: Vogelmeier C, Hederer B, Glaab T, Schmidt H, Rutten-van Molken MP, Beeh KM, Rabe KF, Fabbri LM; POET-COPD Investigators. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med. 2011 Mar 24;364(12):1093-1103. doi: 10.1056/NEJMoa1008378.
citation: Beeh KM, Hederer B, Glaab T, Muller A, Rutten-van Moelken M, Kesten S, Vogelmeier C. Study design considerations in a large COPD trial comparing effects of tiotropium with salmeterol on exacerbations. Int J Chron Obstruct Pulmon Dis. 2009;4:119-25. Epub 2009 Apr 15.